Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US-11021458-B2 · Jun 1, 2021 · US
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US11370774B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11370774-B2 |
| Application number | US-202117202965-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 16, 2021 |
| Priority date | Apr 6, 2018 |
| Publication date | Jun 28, 2022 |
| Grant date | Jun 28, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, or a pharmaceutically acceptable salt thereof, having the following structure: 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 3. The compound of claim 1 , wherein the compound is in the form of a hydrochloride salt.
Assignees
Inventors
Classifications
- C07D239/70Primary
condensed with carbocyclic rings or ring systems · CPC title
Drugs for immunological or allergic disorders · CPC title
Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)} · CPC title
of the kidneys · CPC title
- C07D401/10Primary
linked by a carbon chain containing aromatic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11370774B2 cover?
- Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
- Who is the assignee on this patent?
- Biocryst Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D239/70. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).